Bo Jesper Hansen (1958), Portfolio Advisor
Dr Bo Jesper Hansen, M.D., PhD, recently (May 2016) resignedl as the Executive Chairman of the Board of SOBI AB (Swedish Orphan Biovitrum AB) which is biotech company listed on the Swedish stock exchange with a market capitalization of around 3,5 billion euros. He is Chairman of Karolinska Development AB and is also non-executive Director of the biotech / pharma companies Orphazyme ApS, Newron Pharmaceuticals SpA, CMC AB and Genspera Inc. Dr Hansen served as CEO and President and as Director to the Board of Swedish Orphan International (1998-2010) until the merger with Biovitrum, forming Swedish Orphan Biovitrum. He also was non-executive Director of Gambro until its acquisition by Baxter, and Zymenex, until its acquisition by Chiesi. Dr. Hansen was the Executive Chairman of Topotarget and in this role led the merger with BioAlliance forming OnXeo. He founded Scandinavian Medical Research during which he served as Medical Advisor for the multinationals Synthélabo, Pfizer, Pharmacia and Yamanouchi Pharmaceutical. He also has been a board member with the companies TopoTarget A/S, CMC AB, MipSalus Aps, Kontrast AB, Hyperion Therapeutics, Inc. Newron Pharmaceuticals S.p.A, Novagali Pharma S.A. and VivolutionA/S.
He has an extensive knowledge within clinical study design, regulatory, pharmacovigilance,and business development. He has an M.D. in Urology and a Ph.D. from the University of Copenhagen. Mr Krol and Mr Hansen first met as a member of the supervisory board of biotech company Orphazyme S.p.A.